BIOPHYTIS (EPA:ALBPS) - Biophytis Receives €980,000 DeepTech Funding from BPI France for the development of Macuneos (BIO201) in dry AMD

Transparency directive : regulatory news

29/04/2021 08:00

Press release

  Biophytis Receives EUR980,000 DeepTech Funding from BPI France for the
               development of Macuneos (BIO201) in dry AMD

* DeepTech funding supports advanced and highly differentiating biotech
  projects with significant commercial potential
* Biophytis plans to initiate Phase 1 clinical trial in the second half of
  2021

Paris, France, Cambridge (Massachusetts, United States), April 29 2021, 8AM CET
- Biophytis SA (Euronext Growth Paris: ALBPS), a clinical-stage biotechnology
company focused on the development of therapeutics aimed at slowing the
degenerative processes associated with aging and improving functional outcomes
for patients suffering from age-related diseases, including severe respiratory
failure in patients suffering from COVID-19, today announces it was granted a
non-dilutive funding of EUR980,000 from the public investment bank BPI France's
DeepTech program, for its MACA program of Macuneos (BIO201) in dry Age-Related
Macular Degeneration (AMD).

The DeepTech program aims to boost highly innovative and breakthrough projects
emerging from fundamental research with attractive dedicated financing tools.
The funding consists of a conditional advance of EUR600,000 and a grant of
EUR380,000 which will complement existing financing for preclinical studies of
Biophytis' MACA clinical program in treatment of dry AMD, an age-related
degeneration of the macula, the central part of the retina. AMD is one of the
leading causes of irreversible vision loss and blindness in people over the age
of 50.

Stanislas Veillet, President and CEO of Biophytis, said: "We are pleased with
this funding award, which recognizes the potential of Biophytis' Macuneos
(BIO201), which has demonstrated promising results in preclinical studies.
There is still no available treatment for dry AMD and the loss of vision has a
significant impact on patients' quality of life. Macuneos (BIO201) has the
potential to address a major unmet medical need and we look forward to further
investigating it in clinical phases."

Biophytis plans to initiate a Phase 1 clinical trial (MACA-PK) in healthy
volunteers in the second half of 2021, subject to regulatory review and
approval as well as COVID-19-related delays and the impact of the pandemic on
operational capabilities.

Macuneos (BIO201) is an orally administered small molecule in development for
the treatment of diseases of the retina, or retinopathies. It is a
plant-derived pharmaceutical-grade purified 9 cis-norbixin, or norbixin.
Biophytis has completed preclinical cellular and animal studies of Macuneos
(BIO201) for the treatment of retinopathies.

Biophytis believes that the results from preclinical studies support continued
investigation to whether Macuneos (BIO201) may stimulate biological resilience
and protect the retina against phototoxic damage that leads to vision loss. Dry
AMD is a common eye disorder among people over the age of 50 that affects
central vision, impairing functions such as reading, driving, and facial
recognition, and has a major impact on quality of life and the ability to live
independently. There are currently no approved drugs for dry AMD. Based on
estimates from publicly available information, AMD affects approximately 8.5%
of the global population (ages 45 to 85) and is expected to increase over time
as the population ages.

About BIOPHYTIS

Biophytis SA is a clinical-stage biotechnology company specialized in the
development of therapeutics that are aimed at slowing the degenerative
processes associated with aging and improving functional outcomes for patients
suffering from age-related diseases, including severe respiratory failure in
patients suffering from COVID-19.
Sarconeos (BIO101), our leading drug candidate, is a small molecule,
administered orally, being developed as a treatment for sarcopenia in a Phase 2
clinical trial in the United States and Europe (SARA-INT). It is also being
studied in a clinical two-part Phase 2-3 study (COVA) for the treatment of
severe respiratory manifestations of COVID-19 in Europe, Latin America, and the
US. A pediatric formulation of Sarconeos (BIO101) is being developed for the
treatment of Duchenne Muscular Dystrophy (DMD).
The company is based in Paris, France, and Cambridge, Massachusetts. The
company's common shares are listed on Euronext Growth (Ticker: ALBPS -ISIN:
FR0012816825) and ADSs are listed on Nasdaq Capital Market (Ticker BPTS - ISIN:
US09076G1040).
For more information visit www.biophytis.com

Disclaimer

This press release contains forward-looking statements. Forward-looking
statements include all statements that are not historical facts. In some cases,
you can identify these forward-looking statements by the use of words such as
"outlook," "believes," "expects," "potential," "continues," "may," "will,"
"should," "could," "seeks," "predicts," "intends," "trends," "plans,"
"estimates," "anticipates" or the negative version of these words or other
comparable words. These forward-looking statements include statements regarding
Biophytis' anticipated timing for its Interim Analysis of Part 1 and release of
full study results. Such forward-looking statements are based on assumptions
that Biophytis considers to be reasonable. However, there can be no assurance
that the statements contained in such forward-looking statements will be
verified, which are subject to various risks and uncertainties including,
without limitation, delays in patient recruitment or retention, interruptions
in sourcing or supply chain, its ability to obtain the necessary regulatory
authorizations, COVID-19-related delays, and the impact of the current pandemic
on the Company's clinical trials. The forward-looking statements contained in
this press release are also subject to risks not yet known to Biophytis or not
currently considered material by Biophytis. Accordingly, there are or will be
important factors that could cause actual outcomes or results to differ
materially from those indicated in these statements. In France, please also
refer to the "Risk Factors" section of the Company's Annual 2019 Report and the
Company's Half Year 2020 Report available on BIOPHYTIS website
(www.biophytis.com). We undertake no obligation to publicly update or review
any forward-looking statement, whether as a result of new information, future
developments or otherwise, except as required by law.

Biophytis Contact for Investor Relations
Evelyne Nguyen, CFO
evelyne.nguyen@biophytis.com

Media contact
Life Sci Advisors
Sophie Baumont/Chris Maggos
E: sophie@lifesciadvisors.com
T: +33 6 27 74 74 49

Investor Relations
LifeSci Advisors, LLC
Ligia Vela-Reid
E: lvela-reid@lifesciadvisors.com

BIOPHYTIS's latest news

14/05/2024 07:00

BIOPHYTIS (EPA:ALBPS) - Biophytis Receives €980,000 DeepTech Funding from BPI France for the development of Macuneos (BIO201) in dry AMD

Transparency directive : regulatory news

BIOPHYTIS's latest news

Other stories